Review



microarray dna methylation signature  (Epimmune Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Epimmune Inc microarray dna methylation signature
    Microarray Dna Methylation Signature, supplied by Epimmune Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/array-based+analysis+of+dna+methylation+patterns/microarray+dna+methylation+signature/pm39684677-46-7-11
    Average 90 stars, based on 1 article reviews
    microarray dna methylation signature - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Microarray:

    Article Title: PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Article Snippet: This article is protected by copyright.. All rights reserved.. Aims: PD-L1 and tumor mutation burden (TMB) are the most widely used immunotherapy biomarkers to identify populations who would attain clinical benefit, with the higher values predicting the better therapeutic efficacy.

    Article Title: Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy
    Article Snippet: .. An epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) was created in a sample of 34 NSCLC patients receiving pembrolizumab or nivolumab. ..

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].

    DNA Methylation Assay:

    Article Title: PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
    Article Snippet: This article is protected by copyright.. All rights reserved.. Aims: PD-L1 and tumor mutation burden (TMB) are the most widely used immunotherapy biomarkers to identify populations who would attain clinical benefit, with the higher values predicting the better therapeutic efficacy.

    Article Title: Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer
    Article Snippet: .. In another study involving stage IV NSCLC patients treated with anti-PD-1 agents, a DNA methylation signature known as EPIMMUNE was found to correlate with both PFS and OS ( ). ..

    Article Title: Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies.
    Article Snippet: .. Importantly, EPIMMUNE is a DNA methylation signature that has been associated with ICI efficacy and overall survival in NSCLC patients [112]. ..

    Article Title: Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy
    Article Snippet: .. An epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) was created in a sample of 34 NSCLC patients receiving pembrolizumab or nivolumab. ..

    Article Title: Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
    Article Snippet: .. Importantly, EPIMMUNE is a DNA methylation signature that has been associated with ICI efficacy and overall survival in NSCLC patients [ ]. ..

    Article Title: Tumour-infiltrating lymphocytes: from prognosis to treatment selection
    Article Snippet: .. Duruisseaux et al. found a correlation between epigenetic features based on DNA methylation signature (EPIMMUNE) and clinical benefit with PD-1 blockade in NSCLC. ..

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].

    Biomarker Discovery:

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].

    Derivative Assay:

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].

    Methylation:

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].

    Marker:

    Article Title: Tumor Methylation Burden (TMeB) in Non-Small Cell Lung Cancer: A New Way of Thinking About Epigenetics.
    Article Snippet: .. The epigenomic profile was based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumor samples from 142 patients treated with nivolumab or pembrolizumab (34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort). .. An intriguing result came from the EPIMMUNE signature (forkhead box P1, FOXP1 status), since this was significantly associated with progression-free survival (PFS) and overall survival (OS), suggesting that EPIMMUNE may be a good predictor of anti-PD-1-ICI response [24].



    Similar Products

    array-based analysis of dna methylation patterns  (Epigenomics ag)
    90
    Epigenomics ag array-based analysis of dna methylation patterns
    Array Based Analysis Of Dna Methylation Patterns, supplied by Epigenomics ag, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/array-based+analysis+of+dna+methylation+patterns/genome+wide+dna+methylation+assays/pmc05805678__41467_2018_3025_MOESM2_ESM-37-11-4
    Average 90 stars, based on 1 article reviews
    array-based analysis of dna methylation patterns - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results